Follow

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2022

05 December 2022 - 11:00

Zinzino group revenue increased with a total of 13%, compared with the previous year.

The revenue in November for Zinzino's sales markets increased by 13% and amounted to SEK 159.6 (140.8) million. Faun Pharma's external sales increased by 5% and amounted to SEK 5.8 (5.5) million. Overall, the Group increased revenues by 13% to SEK 165.4 (146.3) million compared with the previous year.

Accumulated revenue for January – November 2022 increased by 7% to SEK 1312.6 (1222.4) million.

Revenues were distributed as follows:

Regions, mSEK 22-Nov 21-Nov Change YTD 2022 YTD 2021 Change
The Nordics 27.9 32.0 -13% 292.0 332.5 -12%
Central Europe 38.1 24.9 53% 262.4 205.5 28%
East Europe 46.1 41.3 12% 314.3 303.6 4%
South & West Europe 19.4 15.5 25% 149.6 129.9 15%
The Baltics 11.0 10.3 7% 70.5 68.5 3%
North America 7.8 4.7 66% 71.4 45.2 58%
Asia-Pacific 7.8 11.5 -32% 71.6 79.6 -10%
Africa 1.5 0.6 150% 8.8 0.6 1367%
Zinzino 159.6 140.8 13% 1240.6 1165.4 6%
Faun Pharma 5.8 5.5 5% 72.0 57.0 26%
Zinzino Group 165.4 146.3 13% 1312.6 1222.4 7%

Countries in regions:

-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden

-Central Europe: Austria, Germany, Switzerland

-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania

-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland

-The Baltics: Estonia, Latvia, Lithuania

-North America: Canada, USA

-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

-Africa: South Africa

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:

[email protected]

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]


This disclosure contains information that Zinzino is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 05-12-2022 11:00 CET.

Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available on more than 100 markets across the world. Zinzino owns the Swiss, biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, the US and Australia.

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Zinzino Holding AB
Zinzino is a direct sales company which offers products focusing on nutritional supplements, skincare, and lifestyle products. The Company operates in three segments Zinzino; Faun and VMA Life....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More